MorphoSys’s clinical pipeline now comprises nine partnered programs in Phase 1 and five in Phase 2 development as well as the company’s proprietary programs MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and MOR208, which is in a Phase 1 trial for chronic lymphocytic leukemia.
MorphoSys chief scientific officer Marlies Sproll said that the seventh clinical milestone with partners in 2010 surpasses their original expectations for the year of up to six such events.
"Today’s news marks another milestone for the HuCAL platform, clearly illustrating the success of this technology," Sproll said.